Results 61 to 70 of about 112,750 (251)

No harm from angiotensin-converting enzyme inhibitors or angiotensin receptor inhibitors in patients with COVID-19. Results of a prospective study on a hospital-based cohort

Italian Journal of Medicine, 2020
This study aims to assess the effect of angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor inhibitors (ARBs) on the course of COVID-19.
Gian Paolo Anzola, Clara Bartolaminelli, Gina Alessandra Gregorini, Chiara Coazzoli, Francesca Gatti, Alessandra Mora, Dimitrios Charalampakis, Andrea Palmigiano, Michele De Simone, Alice Comini, Erica Dellaglio, Salvatore Cassetti, Maurizio Chiesa, Francesca Spedini, Patrizia d'Ottavi, Maria Cristina Savio   +15 more
doaj   +1 more source

The history of inhibitors of angiotensin converting enzyme

, 2001
This review paper by Sir John Vane, The Nobel Prize Laureate for the first time reveals the insides of discovery of inhibitors of angiotensin converting enzyme (ACE-1), presently known as important drugs for the treatment of hypertension, congestive heart failure and coronary artery disease.
openaire   +2 more sources

Platelet FcɣRIIa Expression Refines Clinical Risk Assessment After Myocardial Infarction

Catheterization and Cardiovascular Interventions, EarlyView.
ABSTRACT Background In patients with myocardial infarction (MI), quantifying expression of platelet FcɣRIIa (pFCG) stratifies risk of subsequent MI, stroke, and death. Aims Assess the prognostic implications of clinical risk alone and in combination with the pFCG test.
David J. Schneider, Sean R. McMahon, Dominick J. Angiolillo, Alexander C. Fanaroff, Homam Ibrahim, Patrick K. Hohl, Brett L. Wanamaker, Mark B. Effron, Peter M. DiBattiste, behalf of the investigators   +9 more
wiley   +1 more source

Plasma Exosome Metabolomics Reveal Stage‐Specific Alterations in Elderly Women With Premetabolic and Metabolic Syndrome

Chronic Diseases and Translational Medicine, EarlyView.
Shared differential metabolites identified across the three sample groups. (A) Venn diagram of differential metabolites between the two comparison groups; Based on the detected levels of these overlapping differential metabolites, (B) d‐Arabitol, (C) Triclosan, (D) Iloprost, (E) Tetracosanoic acid, and (F) Omeprazole sulfone. Box plots were constructed
Mengtao Qian, Dan Nie, Qianyi Gao, Xingbo Mo, Huan Zhang   +4 more
wiley   +1 more source

Impact of CYP2C19 and CYP3A4 Inhibitor Use on Clopidogrel Clinical Effectiveness in CYP2C19 Genotyped Patients Undergoing Percutaneous Coronary Intervention

Clinical Pharmacology &Therapeutics, EarlyView.
CYP2C19 and CYP3A4 contribute to clopidogrel bioactivation. CYP2C19 no‐function alleles diminish clopidogrel's antiplatelet effects and clinical effectiveness. Coadministration of either a CYP2C19 or a CYP3A4 inhibitor may also reduce clopidogrel's antiplatelet effects and lead to phenoconversion in patients without a CYP2C19 no‐function allele (normal/
Danwei Shao, Jean G. Malavé, Joseph S. Rossi, Francesco Franchi, Ellen C. Keeley, Dominick J. Angiolillo, George A. Stouffer, Larisa H. Cavallari, Craig R. Lee   +8 more
wiley   +1 more source

Socio‐economic inequalities and heart failure morbidity and mortality: A systematic review and data synthesis

ESC Heart Failure, Volume 12, Issue 2, Page 927-941, April 2025.
Abstract Socio‐economic status (SES) has been associated with incident and prevalent heart failure (HF), as well as its morbidity and mortality. However, the precise nature of the relationship between SES and HF remains unclear due to inconsistent data. This study aims to provide a comprehensive assessment and data synthesis of the relationship between
Abdul Shakoor, Willemijn A. van Maarschalkerwaart, Jeroen Schaap, Rudolf A. de Boer, Nicolas M. van Mieghem, Eric H. Boersma, Loek van Heerebeek, Jasper J. Brugts, Robert M.A. van der Boon   +8 more
wiley   +1 more source

Incident heart failure: comparing management and outcome in primary and hospital settings in Western Sweden 2008–2017

ESC Heart Failure, Volume 12, Issue 2, Page 832-838, April 2025.
Abstract Aim Heart failure (HF) is a highly prevalent condition managed in both primary care (PC) and hospital care (HC)‐based settings. HF patients managed in these two settings may differ in their demography, comorbidities and outcomes, so we aimed to compare the patient management in PC and HC in the Västra Götaland Region (VGR) in Sweden.
Xiaojing Chen, Aldina Pivodic, Maria Schaufelberger, Annika Rosengren, Michael Fu   +4 more
wiley   +1 more source

Transthyretin amyloid cardiomyopathy: Literature review and red‐flag symptom clusters for each cardiology specialty

ESC Heart Failure, Volume 12, Issue 2, Page 955-967, April 2025.
Abstract Wild‐type transthyretin amyloid cardiomyopathy (ATTRwt‐CM) is a progressive and infiltrative cardiac disorder that may cause fatal consequences if left untreated. The estimated survival time from diagnosis is approximately 3–6 years. Because of the non‐specificity of initial symptom manifestation and insufficient awareness among treating ...
Yasuhiro Izumiya, Toru Kubo, Jin Endo, Seiji Takashio, Masatoshi Minamisawa, Jun Hamada, Tomonori Ishii, Hajime Abe, Hiroaki Konishi, Kenichi Tsujita   +9 more
wiley   +1 more source

Response of blood pressure to maximum exercise in hypertensive patients under different therapeutic programs

Arquivos Brasileiros de Cardiologia, 2000
OBJECTIVE: To evaluate the behavior of blood pressure during exercise in patients with hypertension controlled by frontline antihypertension drugs. METHODS: From 979ergometric tests we retrospectively selected 49 hipertensive patients (19 males). The age
Carreira Maria Angela Magalhães de Queiroz, Ribeiro Jamila Costa, Caldas José Antônio, Tavares Leandro Reis, Nani Eduardo   +4 more
doaj  

Prognostic role of high‐sensitivity cardiac troponin T in patients with cardiac sarcoidosis: insights from ILLUMINATE‐CS

ESC Heart Failure, Volume 12, Issue 2, Page 869-878, April 2025.
Abstract Aims The prognostic role of high‐sensitivity cardiac troponin T (hs‐cTnT) as a biomarker in patients with cardiac sarcoidosis (CS) has yet to be fully determined, especially when compared with B‐type natriuretic peptide (BNP). Methods and Results In this post‐hoc analysis of the ILLUMINATE‐CS (ILLUstration of the Management and prognosIs of ...
Yuichi Baba, Toru Kubo, Takeru Nabeta, Yuya Matsue, Takeshi Kitai, Yoshihisa Naruse, Tatsunori Taniguchi, Hidekazu Tanaka, Takahiro Okumura, Kenji Yoshioka, Hiroaki Kitaoka   +10 more
wiley   +1 more source